Ray CAMPHAUSEN

Person

Wayland, MA, US

People

Patents Grantslast 30 patents

Information Patent Grant
Fibronectin binding domains with reduced immunogenicity
- Patent number 11,408,093
- Issue date Aug 9, 2022
- Bristol-Myers Squibb Company
- Jonathan Davis
- C40 - COMBINATORIAL CHEMISTRY
Information Patent Grant
Fibronectin binding domains with reduced immunogenicity
- Patent number 11,279,751
- Issue date Mar 22, 2022
- Bristol-Myers Squibb Company
- Jonathan Davis
- C40 - COMBINATORIAL CHEMISTRY
Information Patent Grant
Methods of treating diseases associated with fibrosis using modifie...
- Patent number 11,248,031
- Issue date Feb 15, 2022
- Bristol-Myers Squibb Company
- Paul E. Morin
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Serum albumin-binding fibronectin type III domains
- Patent number 11,203,630
- Issue date Dec 21, 2021
- Bristol-Myers Squibb Company
- Tracy S. Mitchell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fibronectin based scaffold proteins having improved stability
- Patent number 11,161,893
- Issue date Nov 2, 2021
- Bristol-Myers Squibb Company
- Ray Camphausen
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Targeted therapeutics based on engineered proteins for tyrosine kin...
- Patent number 11,149,077
- Issue date Oct 19, 2021
- Bristol-Myers Squibb Company
- Ray Camphausen
- C40 - COMBINATORIAL CHEMISTRY
Information Patent Grant
Bispecific EGFR/IGFIR binding molecules
- Patent number 10,954,286
- Issue date Mar 23, 2021
- Bristol-Myers Squibb Company
- Stuart Emanuel
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fibronectin based scaffold domain proteins that bind PCSK9
- Patent number 10,947,297
- Issue date Mar 16, 2021
- Bristol-Myers Squibb Company
- Ray Camphausen
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Serum albumin binding molecules
- Patent number 10,934,572
- Issue date Mar 2, 2021
- Bristol-Myers Squibb Company
- Michael L. Gosselin
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Targeted therapeutics based on engineered proteins that bind EGFR
- Patent number 10,781,247
- Issue date Sep 22, 2020
- Bristol-Myers Squibb Company
- Ray Camphausen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Method of treating cancer by administering multivalent fibronectin...
- Patent number 10,774,130
- Issue date Sep 15, 2020
- Bristol-Myers Squibb Company
- Ray Camphausen
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Fibronectin binding domains with reduced immunogenicity
- Patent number 10,604,556
- Issue date Mar 31, 2020
- Bristol-Myers Squibb Company
- Jonathan Davis
- C40 - COMBINATORIAL CHEMISTRY
Information Patent Grant
Fibronectin binding domains with reduced immunogenicity
- Patent number 10,464,995
- Issue date Nov 5, 2019
- Bristol-Myers Squibb Company
- Jonathan Davis
- C40 - COMBINATORIAL CHEMISTRY
Information Patent Grant
Serum albumin-binding fibronectin type III domains
- Patent number 10,442,851
- Issue date Oct 15, 2019
- Bristol-Myers Squibb Company
- Tracy S. Mitchell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Methods of treating diseases associated with fibrosis using modifie...
- Patent number 10,377,806
- Issue date Aug 13, 2019
- Bristol-Myers Squibb Company
- Paul E. Morin
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fibronectin based scaffold proteins having improved stability
- Patent number 10,273,286
- Issue date Apr 30, 2019
- Bristol-Myers Squibb Company
- Ray Camphausen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Methods of treating cancer by administering IGF-IR binding molecules
- Patent number 10,221,232
- Issue date Mar 5, 2019
- Bristol-Myers Squibb Company
- Ray Camphausen
- C40 - COMBINATORIAL CHEMISTRY
Information Patent Grant
Serum albumin binding molecules
- Patent number 10,221,438
- Issue date Mar 5, 2019
- Bristol-Myers Squibb Company
- Michael L. Gosselin
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Fc fusion proteins comprising novel linkers or arrangements
- Patent number 10,214,579
- Issue date Feb 26, 2019
- Bristol-Myers Squibb Company
- Ray Camphausen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Therapeutic uses of modified FGF-21 polypeptides
- Patent number 10,189,883
- Issue date Jan 29, 2019
- Bristol-Myers Squibb Company
- Paul E. Morin
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules
- Patent number 10,183,987
- Issue date Jan 22, 2019
- Bristol-Myers Squibb Company
- Stuart Emanuel
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Targeted therapeutics based on engineered proteins that bind EGFR
- Patent number 9,920,108
- Issue date Mar 20, 2018
- Bristol-Myers Squibb Company
- Ray Camphausen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Multivalent fibronectin based scaffold domain proteins
- Patent number 9,902,762
- Issue date Feb 27, 2018
- Bristol-Myers Squibb Company
- Ray Camphausen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fibronectin based scaffold domain proteins that bind PCSK9
- Patent number 9,856,309
- Issue date Jan 2, 2018
- BRISTOL-MYERS SQUIBB COMPANY
- Ray Camphausen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Method of treating cancer by administering EGFR and EGFR/IGFIR bind...
- Patent number 9,771,411
- Issue date Sep 26, 2017
- Bristol-Myers Squibb Company
- Stuart Emanuel
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fibronectin binding domains with reduced immunogenicity
- Patent number 9,765,132
- Issue date Sep 19, 2017
- Bristol-Myers Squibb Company
- Jonathan Davis
- C40 - COMBINATORIAL CHEMISTRY
Information Patent Grant
Modified FGF-21 polypeptides comprising an internal deletion and us...
- Patent number 9,631,004
- Issue date Apr 25, 2017
- Bristol-Myers Squibb Company
- Paul E. Morin
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fibronectin based scaffold proteins having improved stability
- Patent number 9,562,089
- Issue date Feb 7, 2017
- Bristol-Myers Squibb Company
- Ray Camphausen
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Serum albumin binding molecules
- Patent number 9,540,424
- Issue date Jan 10, 2017
- Bristol-Myers Squibb Company
- Michael L. Gosselin
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fibronectin binding domains with reduced immunogenicity
- Patent number 9,522,951
- Issue date Dec 20, 2016
- Bristol-Myers Squibb Company
- Jonathan Davis
- C40 - COMBINATORIAL CHEMISTRY

Patents Applicationslast 30 patents

Information Patent Application
FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
- Publication number 20240239870
- Publication date Jul 18, 2024
- Bristol-Myers Squibb Company
- Ray Camphausen
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY
- Publication number 20230183885
- Publication date Jun 15, 2023
- Bristol-Myers Squibb Company
- Jonathan DAVIS
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY
- Publication number 20220275535
- Publication date Sep 1, 2022
- Bristol-Myers Squibb Company
- Jonathan DAVIS
- C40 - COMBINATORIAL CHEMISTRY
Information Patent Application
SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
- Publication number 20220204589
- Publication date Jun 30, 2022
- Bristol-Myers Squibb Company
- Tracy S. MITCHELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Methods of treating diseases associated with fibrosis using modifie...
- Publication number 20220185856
- Publication date Jun 16, 2022
- Bristol-Myers Squibb Company
- Paul E. MORIN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY
- Publication number 20220119495
- Publication date Apr 21, 2022
- Bristol-Myers Squibb Company
- Ray Camphausen
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
- Publication number 20210277089
- Publication date Sep 9, 2021
- Bristol-Myers Squibb Company
- Ray Camphausen
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
- Publication number 20210122805
- Publication date Apr 29, 2021
- Bristol-Myers Squibb Company
- Ray CAMPHAUSEN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
- Publication number 20210040181
- Publication date Feb 11, 2021
- Bristol-Myers Squibb Company
- Ray Camphausen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
- Publication number 20210017252
- Publication date Jan 21, 2021
- Bristol-Myers Squibb Company
- Ray CAMPHAUSEN
- C07 - ORGANIC CHEMISTRY
Information Patent Application
FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY
- Publication number 20200339662
- Publication date Oct 29, 2020
- Bristol-Myers Squibb Company
- Jonathan Davis
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY
- Publication number 20200123229
- Publication date Apr 23, 2020
- Bristol-Myers Squibb Company
- Jonathan DAVIS
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
- Publication number 20200048328
- Publication date Feb 13, 2020
- Bristol-Myers Squibb Company
- Tracy S. MITCHELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Modified FGF-21 Polypeptides and Uses Thereof
- Publication number 20190382460
- Publication date Dec 19, 2019
- Bristol-Myers Squibb Company
- Paul E. MORIN
- C07 - ORGANIC CHEMISTRY
Information Patent Application
FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY
- Publication number 20190263892
- Publication date Aug 29, 2019
- Bristol-Myers Squibb Company
- Ray Camphausen
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
- Publication number 20190248872
- Publication date Aug 15, 2019
- Bristol-Myers Squibb Company
- Ray CAMPHAUSEN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
SERUM ALBUMIN BINDING MOLECULES
- Publication number 20190203248
- Publication date Jul 4, 2019
- Bristol-Myers Squibb Company
- Michael L. GOSSELIN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KIN...
- Publication number 20190202894
- Publication date Jul 4, 2019
- Bristol-Myers Squibb Company
- Ray CAMPHAUSEN
- C40 - COMBINATORIAL CHEMISTRY
Information Patent Application
BISPECIFIC EGFR/IGFIR BINDING MOLECULES
- Publication number 20190153069
- Publication date May 23, 2019
- Bristol-Myers Squibb Company
- Stuart EMANUEL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
- Publication number 20180265572
- Publication date Sep 20, 2018
- Bristol-Myers Squibb Company
- Ray CAMPHAUSEN
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Modified FGF-21 Polypeptides and Uses Thereof
- Publication number 20180243375
- Publication date Aug 30, 2018
- Bristol-Myers Squibb Company
- Paul E. MORIN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
- Publication number 20180244755
- Publication date Aug 30, 2018
- Bristol-Myers Squibb Company
- Ray Camphausen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
- Publication number 20180201665
- Publication date Jul 19, 2018
- Bristol-Myers Squibb Company
- Ray Camphausen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
BISPECIFIC EGFR/IGFIR BINDING MOLECULES
- Publication number 20180037631
- Publication date Feb 8, 2018
- Bristol-Myers Squibb Company
- Stuart EMANUEL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF
- Publication number 20170189486
- Publication date Jul 6, 2017
- Bristol-Myers Squibb Company
- Paul E. MORIN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KIN...
- Publication number 20170190761
- Publication date Jul 6, 2017
- Bristol-Myers Squibb Company
- Ray CAMPHAUSEN
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
- Publication number 20170174748
- Publication date Jun 22, 2017
- Bristol-Myers Squibb Company
- Tracy S. MITCHELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY
- Publication number 20170166627
- Publication date Jun 15, 2017
- Bristol-Myers Squibb Company
- Ray CAMPHAUSEN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
SERUM ALBUMIN BINDING MOLECULES
- Publication number 20170145464
- Publication date May 25, 2017
- Bristol-Myers Squibb Company
- Michael L. GOSSELIN
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY
- Publication number 20170137494
- Publication date May 18, 2017
- Bristol-Myers Squibb Company
- Jonathan DAVIS
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Ray CAMPHAUSEN

Person

Patents Grantslast 30 patents

Fibronectin binding domains with reduced immunogenicity

Fibronectin binding domains with reduced immunogenicity

Methods of treating diseases associated with fibrosis using modifie...

Serum albumin-binding fibronectin type III domains

Fibronectin based scaffold proteins having improved stability

Targeted therapeutics based on engineered proteins for tyrosine kin...

Bispecific EGFR/IGFIR binding molecules

Fibronectin based scaffold domain proteins that bind PCSK9

Serum albumin binding molecules

Targeted therapeutics based on engineered proteins that bind EGFR

Method of treating cancer by administering multivalent fibronectin...

Fibronectin binding domains with reduced immunogenicity

Fibronectin binding domains with reduced immunogenicity

Serum albumin-binding fibronectin type III domains

Methods of treating diseases associated with fibrosis using modifie...

Fibronectin based scaffold proteins having improved stability

Methods of treating cancer by administering IGF-IR binding molecules

Serum albumin binding molecules

Fc fusion proteins comprising novel linkers or arrangements

Therapeutic uses of modified FGF-21 polypeptides

Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules

Targeted therapeutics based on engineered proteins that bind EGFR

Multivalent fibronectin based scaffold domain proteins

Fibronectin based scaffold domain proteins that bind PCSK9

Method of treating cancer by administering EGFR and EGFR/IGFIR bind...

Fibronectin binding domains with reduced immunogenicity

Modified FGF-21 polypeptides comprising an internal deletion and us...

Fibronectin based scaffold proteins having improved stability

Serum albumin binding molecules

Fibronectin binding domains with reduced immunogenicity

Patents Applicationslast 30 patents

FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9

FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY

FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY

SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS

Methods of treating diseases associated with fibrosis using modifie...

FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY

FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9

Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS

TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR

MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS

FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY

FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY

SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS

Modified FGF-21 Polypeptides and Uses Thereof

FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY

Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS

SERUM ALBUMIN BINDING MOLECULES

TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KIN...

BISPECIFIC EGFR/IGFIR BINDING MOLECULES

MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS

Modified FGF-21 Polypeptides and Uses Thereof

TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR

FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9

BISPECIFIC EGFR/IGFIR BINDING MOLECULES

MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF

TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KIN...

SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS

FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY

SERUM ALBUMIN BINDING MOLECULES

FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY